Please login to the form below

Not currently logged in
Email:
Password:

GSK Biologicals signs Alzheimer's deal with AFFiRiS

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates.

The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. This allows the development of proteins that bind to the disease-causing human proteins that are central to the pathology of Alzheimer's disease.

Jean Stephenne, president and general manager of GlaxoSmithKline Biologicals said: "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty payments. In the event of the vaccines reaching full commercial success and gaining government authority approval, the value of the agreement could reach £334m.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics